1660-P：在美国和欧盟糖尿病患者中检查月经对糖尿病管理的影响

IF 7.5 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2025-06-20 DOI:10.2337/db25-1660-p

ANURADHA KRISHNAN, SYDNEY CHANEN, TREVOR BELL, TRACY L. BRISTOW, RICHARD WOOD

{"title":"1660-P：在美国和欧盟糖尿病患者中检查月经对糖尿病管理的影响","authors":"ANURADHA KRISHNAN, SYDNEY CHANEN, TREVOR BELL, TRACY L. BRISTOW, RICHARD WOOD","doi":"10.2337/db25-1660-p","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: Hormonal fluctuations associated with menstruation can significantly affect women’s insulin sensitivity and blood glucose levels, posing challenges for diabetes management. Despite affecting half of the population, the intersection of menstruation and diabetes is largely understudied. This study aimed to examine the perceived effects of menstruation on diabetes management and identify critical knowledge and care gaps among people with diabetes (PWD) in the United States (US) and Europe (EU). Methods: From Oct.-Nov. 2024, menstruating PWD in the US (n=686) and EU (n=899) completed an online survey in which they reported overall satisfaction with their glycemic control, the impact of menstruation on their diabetes management, and whether they have discussed these issues with a healthcare provider (HCP). They also provided open-ended feedback on desired changes in diabetes care. Results: Few women report high satisfaction with their overall glycemic control, especially in the EU (19% US vs 14% EU, p&lt;0.05). In both regions, over half of respondents report worsened control during menstruation (56% US, 55% EU), driven by women with Type 1 diabetes (T1) (60% T1 vs 23% T2, p&lt;0.05). Only 36% of women have discussed menstruation’s impact with their HCP, less so among T2 women—particularly non-insulin users (39% T1, 32% T2 on insulin, 17% T2 non-insulin; p&lt;0.05). Qualitatively, many women with diabetes report a lack of information on how hormonal changes affect glycemic control and pump users also express a need for personalized technology that caters to both diabetes and menstruation. Conclusion: These findings highlight unmet needs in gender-based diabetes care. The hormonal changes associated with menstruation must be addressed as key factors in diabetes management and incorporated into clinical discussions, care strategies, and diabetes technologies. Future research should explore the hormonal mechanisms influencing blood glucose and the impact of different menstrual cycle stages on glycemic control. Disclosure A. Krishnan: Research Support; Abbott, Dexcom, Inc., Eli Lilly and Company, diaTribe, Insulet Corporation, Medtronic, Roche Diabetes Care, Tandem Diabetes Care, Inc, Ypsomed AG, LifeScan Diabetes Institute. S. Chanen: Research Support; Abbott, Dexcom, Inc., Eli Lilly and Company, diaTribe, Insulet Corporation, Medtronic, Roche Diabetes Care, Ypsomed AG, Tandem Diabetes Care, Inc, LifeScan Diabetes Institute. T. Bell: Research Support; Abbott, Dexcom, Inc., Tandem Diabetes Care, Inc, Medtronic, MannKind Corporation, Insulet Corporation, CeQur, Beta Bionics, Inc, Eli Lilly and Company, Ypsomed AG. T.L. Bristow: None. R. Wood: Other Relationship; Abbott, diaTribe, Glooko, Inc, Dexcom, Inc., Medtronic, Lilly Diabetes, Insulet Corporation, Sanofi-Aventis U.S., Tandem Diabetes Care, Inc, Zucara Therapeutics.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"51 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"1660-P: Examining the Effects of Menstruation on Diabetes Management among People with Diabetes in the U.S. and EU\",\"authors\":\"ANURADHA KRISHNAN, SYDNEY CHANEN, TREVOR BELL, TRACY L. BRISTOW, RICHARD WOOD\",\"doi\":\"10.2337/db25-1660-p\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction and Objective: Hormonal fluctuations associated with menstruation can significantly affect women’s insulin sensitivity and blood glucose levels, posing challenges for diabetes management. Despite affecting half of the population, the intersection of menstruation and diabetes is largely understudied. This study aimed to examine the perceived effects of menstruation on diabetes management and identify critical knowledge and care gaps among people with diabetes (PWD) in the United States (US) and Europe (EU). Methods: From Oct.-Nov. 2024, menstruating PWD in the US (n=686) and EU (n=899) completed an online survey in which they reported overall satisfaction with their glycemic control, the impact of menstruation on their diabetes management, and whether they have discussed these issues with a healthcare provider (HCP). They also provided open-ended feedback on desired changes in diabetes care. Results: Few women report high satisfaction with their overall glycemic control, especially in the EU (19% US vs 14% EU, p&lt;0.05). In both regions, over half of respondents report worsened control during menstruation (56% US, 55% EU), driven by women with Type 1 diabetes (T1) (60% T1 vs 23% T2, p&lt;0.05). Only 36% of women have discussed menstruation’s impact with their HCP, less so among T2 women—particularly non-insulin users (39% T1, 32% T2 on insulin, 17% T2 non-insulin; p&lt;0.05). Qualitatively, many women with diabetes report a lack of information on how hormonal changes affect glycemic control and pump users also express a need for personalized technology that caters to both diabetes and menstruation. Conclusion: These findings highlight unmet needs in gender-based diabetes care. The hormonal changes associated with menstruation must be addressed as key factors in diabetes management and incorporated into clinical discussions, care strategies, and diabetes technologies. Future research should explore the hormonal mechanisms influencing blood glucose and the impact of different menstrual cycle stages on glycemic control. Disclosure A. Krishnan: Research Support; Abbott, Dexcom, Inc., Eli Lilly and Company, diaTribe, Insulet Corporation, Medtronic, Roche Diabetes Care, Tandem Diabetes Care, Inc, Ypsomed AG, LifeScan Diabetes Institute. S. Chanen: Research Support; Abbott, Dexcom, Inc., Eli Lilly and Company, diaTribe, Insulet Corporation, Medtronic, Roche Diabetes Care, Ypsomed AG, Tandem Diabetes Care, Inc, LifeScan Diabetes Institute. T. Bell: Research Support; Abbott, Dexcom, Inc., Tandem Diabetes Care, Inc, Medtronic, MannKind Corporation, Insulet Corporation, CeQur, Beta Bionics, Inc, Eli Lilly and Company, Ypsomed AG. T.L. Bristow: None. R. Wood: Other Relationship; Abbott, diaTribe, Glooko, Inc, Dexcom, Inc., Medtronic, Lilly Diabetes, Insulet Corporation, Sanofi-Aventis U.S., Tandem Diabetes Care, Inc, Zucara Therapeutics.\",\"PeriodicalId\":11376,\"journal\":{\"name\":\"Diabetes\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2337/db25-1660-p\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db25-1660-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

导论与目的：与月经相关的激素波动会显著影响女性的胰岛素敏感性和血糖水平，给糖尿病的管理带来挑战。尽管影响了一半的人口，但月经和糖尿病之间的关系在很大程度上还没有得到充分的研究。本研究旨在研究月经对糖尿病管理的影响，并确定美国（US）和欧洲（EU）糖尿病患者（PWD）之间的关键知识和护理差距。方法：10 - 11月。2024年，美国（n=686）和欧盟（n=899）的月经期PWD患者完成了一项在线调查，他们报告了对血糖控制的总体满意度，月经对糖尿病管理的影响，以及他们是否与医疗保健提供者（HCP）讨论了这些问题。他们还提供了关于糖尿病治疗预期变化的开放式反馈。结果：很少有女性对自己的总体血糖控制感到满意，尤其是在欧盟（19%美国vs 14%欧盟，p<0.05）。在这两个地区，超过一半的受访者表示月经期间的控制恶化（美国56%，欧盟55%），这是由1型糖尿病（T1）女性造成的（T1期60% vs T2期23%，p<0.05）。只有36%的女性讨论过月经对其HCP的影响，T2期女性——尤其是非胰岛素使用者——的讨论较少(T1期39%，T2期32%胰岛素，T2期17%非胰岛素；p&肝移植;0.05)。从质量上讲，许多患有糖尿病的女性报告缺乏关于激素变化如何影响血糖控制的信息，泵用户也表示需要个性化的技术，以满足糖尿病和月经的需求。结论：这些发现突出了基于性别的糖尿病护理的未满足需求。与月经相关的激素变化必须作为糖尿病管理的关键因素加以处理，并纳入临床讨论、护理策略和糖尿病技术。今后的研究应进一步探讨激素对血糖的影响机制以及月经周期不同阶段对血糖控制的影响。A. Krishnan：研究支持；雅培、Dexcom公司、礼来公司、diaTribe公司、胰岛素公司、美敦力公司、罗氏糖尿病护理公司、Tandem糖尿病护理公司、Ypsomed AG公司、LifeScan糖尿病研究所。S. Chanen：研究支持；雅培公司、Dexcom公司、礼来公司、diaTribe公司、胰岛素公司、美敦力公司、罗氏糖尿病护理公司、Ypsomed公司、Tandem糖尿病护理公司、LifeScan糖尿病研究所。T. Bell：研究支持；雅培、Dexcom、Tandem Diabetes Care、美敦力、MannKind公司、胰岛素公司、CeQur、Beta Bionics公司、礼来公司、Ypsomed AG。T.L.布里斯托：没有。R. Wood：其他关系；雅培、diaTribe、gloko、Dexcom、美敦力、礼来糖尿病、胰岛素公司、赛诺菲-安万特美国公司、Tandem Diabetes Care、Zucara Therapeutics。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

1660-P: Examining the Effects of Menstruation on Diabetes Management among People with Diabetes in the U.S. and EU

Introduction and Objective: Hormonal fluctuations associated with menstruation can significantly affect women’s insulin sensitivity and blood glucose levels, posing challenges for diabetes management. Despite affecting half of the population, the intersection of menstruation and diabetes is largely understudied. This study aimed to examine the perceived effects of menstruation on diabetes management and identify critical knowledge and care gaps among people with diabetes (PWD) in the United States (US) and Europe (EU). Methods: From Oct.-Nov. 2024, menstruating PWD in the US (n=686) and EU (n=899) completed an online survey in which they reported overall satisfaction with their glycemic control, the impact of menstruation on their diabetes management, and whether they have discussed these issues with a healthcare provider (HCP). They also provided open-ended feedback on desired changes in diabetes care. Results: Few women report high satisfaction with their overall glycemic control, especially in the EU (19% US vs 14% EU, p<0.05). In both regions, over half of respondents report worsened control during menstruation (56% US, 55% EU), driven by women with Type 1 diabetes (T1) (60% T1 vs 23% T2, p<0.05). Only 36% of women have discussed menstruation’s impact with their HCP, less so among T2 women—particularly non-insulin users (39% T1, 32% T2 on insulin, 17% T2 non-insulin; p<0.05). Qualitatively, many women with diabetes report a lack of information on how hormonal changes affect glycemic control and pump users also express a need for personalized technology that caters to both diabetes and menstruation. Conclusion: These findings highlight unmet needs in gender-based diabetes care. The hormonal changes associated with menstruation must be addressed as key factors in diabetes management and incorporated into clinical discussions, care strategies, and diabetes technologies. Future research should explore the hormonal mechanisms influencing blood glucose and the impact of different menstrual cycle stages on glycemic control. Disclosure A. Krishnan: Research Support; Abbott, Dexcom, Inc., Eli Lilly and Company, diaTribe, Insulet Corporation, Medtronic, Roche Diabetes Care, Tandem Diabetes Care, Inc, Ypsomed AG, LifeScan Diabetes Institute. S. Chanen: Research Support; Abbott, Dexcom, Inc., Eli Lilly and Company, diaTribe, Insulet Corporation, Medtronic, Roche Diabetes Care, Ypsomed AG, Tandem Diabetes Care, Inc, LifeScan Diabetes Institute. T. Bell: Research Support; Abbott, Dexcom, Inc., Tandem Diabetes Care, Inc, Medtronic, MannKind Corporation, Insulet Corporation, CeQur, Beta Bionics, Inc, Eli Lilly and Company, Ypsomed AG. T.L. Bristow: None. R. Wood: Other Relationship; Abbott, diaTribe, Glooko, Inc, Dexcom, Inc., Medtronic, Lilly Diabetes, Insulet Corporation, Sanofi-Aventis U.S., Tandem Diabetes Care, Inc, Zucara Therapeutics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.